Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 16/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148457 | 1.00 | ALDH1A1 (0.51) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL602162 | 0.91 | EPHX2 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL433358 | 0.91 | EPHX2 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL601086 | 0.91 | EPHX2 (0.57) | ALDH1A1LMNACASP3SENP8SENP6 | |
| SCHEMBL10148472 | 0.89 | SMN1; SMN2 (0.47) | ALDH1A1LMNAEPHX2 | |
| SCHEMBL10148461 | 0.89 | SMN1; SMN2 (0.47) | ALDH1A1LMNAEPHX2 | |
| SCHEMBL601886 | 0.81 | PARP10 (0.45) | ALDH1A1EPHX2FAAH | |
| SCHEMBL601885 | 0.81 | PARP10 (0.45) | ALDH1A1EPHX2FAAH | |
| SCHEMBL10186127 | 0.80 | LMNA (0.51) | ALDH1A1LMNAEPHX2 | |
| SCHEMBL10186405 | 0.80 | LMNA (0.51) | ALDH1A1LMNAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | ALDH1A1 963/4885LMNA 2889/4885CASP3 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.